CD47|SIRPα SUMMIT

CD47|SIRPα SUMMIT

March 18-19 2020 | Boston, MA.

Targeting The Leading “Don’t Eat Me” Signal

Registration Agenda
KEY FEATURES
EXCLUSIVELY DEDICATED

After the great success of the 1st annual CD47|Sirpα summit back in April, this meeting is still the only event solely dedicated to exploring the CD47/SIRPα axis.

PIONEERING SPEAKER FACULTY

Hear from and meet the gurus of the field and the most exciting newcomers from biotech, academia and pharma.

CRUCIAL DISCUSSIONS

Differing approaches to targeting the CD47/SIRPα axis, key fundamental biology, combination therapies and more will be dissected through interactive presentations, panel discussions and open Q&A.

SENIOR-LEVEL NETWORKING

Meet with industry influencers and decision-makers in this intimate and high-quality setting to generate genuinely impactful connections and takeaways.

CURATED LEARNING JOURNEY

Travel from the known to the unknown and the simple to the complex through a carefully constructed end-to-end learning experience.

2 IMPACTFUL DAYS

This space is advancing, that’s why this year, the CD47|SIRPα Summit has been extended to two jam-packed days to allow enough time for crucial topics to be discussed in detail.

WITH VERY PROMISING RESULTS FROM THE FIRST CLINICAL STUDIES, THE DEDICATED CD47/SIRPα SUMMIT IS PERFECTLY TIMED. THIS EVENT PROVIDES THE OPPORTUNITY FOR THOSE WHO HAVE PIONEERED THE SPACE AND ALSO THE NEWCOMERS OF THE INDUSTRY TO GET TOGETHER AND LEARN MORE ABOUT THIS DYNAMIC AND EXCITING FIELD.

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

THE CD47/SIRPα SUMMIT IS A VALUABLE OPPORTUNITY TO SHARE OUR LEARNINGS AND EXPLORE IMPORTANT QUESTIONS ABOUT TARGETING THE MYELOID CHECKPOINT PATHWAY FOR THE TREATMENT OF CANCER.

Hong Wan, Chief Scientific Officer, ALX Oncology

Speakers

Kipp Weiskopf
Kipp Weiskopf
Whitehead Fellow
Whitehead Institute
Kipp Weiskopf
Whitehead Fellow
Whitehead Institute

Kipp Weiskopf, M.D., Ph.D is a clinical fellow in Hematology and Oncology at the Dana-Farber Cancer Institute in Boston, MA. He earned his medical and graduate degrees at Stanford University in the Medical Scientist Training Program. As a member of the laboratory of Irving Weissman, M.D., he characterized the CD47/SIRPα interaction as a myeloid immune checkpoint. He developed engineered SIRPα variants that augment macrophage phagocytosis of cancer and serve as universal enhancers of tumor-opsonizing therapeutic antibodies. He further demonstrated that CD47-blocking therapies can be effective for small cell lung cancer and that CD47-blocking therapies can permit bone marrow transplantation without chemotherapy or radiation. Weiskopf has also developed anti-SIRPα antibodies and showed they enhance phagocytosis in response to tumor-opsonizing antibodies. He further demonstrated that the CD47/SIRPa axis is conserved across evolutionary barriers. More recently, he identified a role for MHC class I molecules as regulators of macrophage activation. Weiskopf is a co-Founder of ALX Oncology, and technology he developed has been licensed to Forty Seven, Inc.

Weiskopf completed his medical training in Internal Medicine Residency Program at Brigham and Women’s Hospital in Boston. He has been awarded the Winston Churchill Scholarship, an NCI Ruth L. Kirschstein NRSA Fellowship, the Harold M. Weintraub Graduate Student Award, the Joanna M. Nicolay Melanoma Foundation Research Scholar Award, and first place in the 2013 Collegiate Inventors Competition. He delivered the PEGS 2018 Young Scientist Keynote address. His ongoing research interests lie in identifying novel myeloid immune checkpoints that regulate macrophage activation within the tumor microenvironment.

Sophia Randolph
Sophia Randolph
Chief Medical Officer
ALX Oncology
Sophia Randolph
Chief Medical Officer
ALX Oncology

Dr. Randolph previously served as Global Franchise Clinical Lead for the IBRANCE® clinical program at Pfizer, and before then as the ZOLINZA® Clinical Lead at Merck. Dr. Randolph received her M.D. and Ph.D. in cellular and molecular biology from University of Michigan and completed her oncology fellowship training at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center. Dr. Randolph received her A.B. in biochemistry from Harvard University.

Timo Van Den Berg
Timo Van Den Berg
Professor of Immunotherapy, Head Department of Blood Cell Research
Sanquin Research, Amsterdam University Medical Center
Timo Van Den Berg
Professor of Immunotherapy, Head Department of Blood Cell Research
Sanquin Research, Amsterdam University Medical Center

Timo Van Den Berg’s group was among the pioneering groups to describe cloning of the inhibitory receptor SIRPα and the first to describe its myeloid-restricted expression. His group have since been studying the physiological functions of CD47-SIRPα interactions and co-discovered, more or less together with the Weissman group at Stanford University, that its acts as an immune checkpoint in the context of antibody therapy in cancer. The method of interfering with the CD47-SIRPα innate immune checkpoint in combination with cancer-targeting monoclonal antibodies in cancer was successfully patented (WO2009/131453), and this was licensed to Synthon Biopharmaceuticals BV who they are collaborating with to develop agents targeting the CD47-SIRPα interaction.

Junjian Liu
Junjian Liu
VP, Biologics Discovery
Innovent Biologics
Junjian Liu
VP, Biologics Discovery
Innovent Biologics
Nicolas Poirier
Nicolas Poirier
Chief Scientific Officer
OSE Immunotherapeutics
Nicolas Poirier
Chief Scientific Officer
OSE Immunotherapeutics

Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneer. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or complement pathways in preclinical models of transplantation and chronic inflammation. He received the awards “Prix de la Recherche Universitaire” by the French journal Le Monde and “New Key Opinion Leader” by the International Society of Transplantation. In 2009, he joined Effimune, a French biotechnology company specialized in immune regulation, where he led R&D programs for 7 years. Upon the merger of Effimune with OSE pharma in 2016, he was appointed Chief Scientific Officer of OSE Immunotherapeutics, a leading biotechnology company in the field of immune activation and regulation with clinical applications in immuno-oncology, autoimmune diseases and transplantation. As CSO, he supported the company’s growth and his R&D team is interested in identification, evaluation and development of innovative immunotherapies to establish, break, regulate or reinforce immune regulation and activation.

Dr Michal Caspi Tal
Dr Michal Caspi Tal
Instructor and Team Lead
Stanford University
Dr Michal Caspi Tal
Instructor and Team Lead
Stanford University

Dr. Michal (Mikki) Tal is an instructor at Stanford University School of Medicine studying host-pathogen interactions with a focus on immune clearance and diversity of immune responses to tick-borne diseases. Michal received her PhD at Yale University in Immunobiology under the mentorship of Akiko Iwasaki. Dr Tal then did her postdoctoral training in the laboratory of Irving Weissman at Stanford where she is currently an instructor leading the infectious disease team and studying the immumodulatory mechanisms by which the CD47-SIRPa axis impacts immune clearance of infectious disease.  Dr. Tal received the Yale Gershon Fellowship, NIH NIAID F30 and F31 pre and postdoctoral fellowships, was selected to give the inaugural Janeway early career lecture at Yale University, and awarded the Emerging Leader Award from Bay Area Lyme Foundation.

Siddhartha Mitra
Siddhartha Mitra
Assistant Professor
University of Colorado
Siddhartha Mitra
Assistant Professor
University of Colorado

Dr. Mitra is currently an Assistant Professor of Pediatrics at the University of Colorado School of Medicine and the Children’s Hospital Colorado in the Division of Hematology-Oncology and Bone Marrow Transplant. His laboratory focuses on immune evasion mechanisms in Adult and Pediatric CNS Malignancies. He was part of the original CD47 disease team as a Senior Scientist at Stanford University.

Taylor Schreiber
Taylor Schreiber
Chief Scientific Officer
Shattuck Labs
Taylor Schreiber
Chief Scientific Officer
Shattuck Labs

Taylor  co-founded  Shattuck Labs  and currently serves  as Chief Scientific Officer  and is a member of the Board  of Directors. Taylor is the lead  inventor of Shattuck’s ARC technology  platform.

Prior  to Shattuck,  Taylor served as  Chief Scientific Officer  of Heat Biologics, Inc. where  he was a co-inventor of significant  elements of Heat’s ImPACT and ComPACT  technology platforms. He was also the co-inventor  of TNFRSF25 agonist technology developed by Pelican  Therapeutics, where he served as Chairman of the Scientific  Advisory Board. Taylor has numerous publications in the field  of tumor immunology and immunotherapy, spanning the subjects of cancer  vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated  immunosuppression and regulatory T cell biology. In 2008, Taylor received the  best overall research award at the National Student Research Forum and in 2011 he  was nominated as a Future Leader in Cancer Research by the American Association for  Cancer Research.

Taylor  received  his M.D. and  Ph.D. degrees from  the Sheila and David  Fuente Program in Cancer  Biology at the University of  Miami Miller School of Medicine.  He received his B.A. in Biology from  Bucknell University.

Weimin Tang
Weimin Tang
Global Business Head & Executive VP
I-Mab Biopharma
Weimin Tang
Global Business Head & Executive VP
I-Mab Biopharma

Dr. Weimin Tang is currently EVP of I-MAB Biopharma, a clinical stage biotech company focus on Immunology and Oncology. He served as Interim CEO/Head of US Business Development, Jiangsu Hengrui Medicine previously and build Hengrui global business development team and clinical operation in Princeton, NJ. He was trained as cancer biologist with PhD in Biochemistry at Rutgers University. He has accumulated more than 20 years of research and business management experiences with global pharmaceutical companies and Biotechs such as Synaptic Pharmaceutical, BMS, JNJ, Sanofi, Crown Biosciences, Hengrui Medicine and I-MAB Biopharma. Through his industry career, he expanded his function from basic biology to high throughput screening, DMPK and business management. Dr. Tang received his Bachelor’s Degree from Zhejiang University, Master Degree from Chinese Academy of Sciences.

Takashi Matozaki
Takashi Matozaki
Professor, Dean of the Graduate School of Medicine
Kobe University
Takashi Matozaki
Professor, Dean of the Graduate School of Medicine
Kobe University

Professor Matozaki is a pioneer researcher who first discovered SIRPα and has been working for the roles of the CD47-SIRPα system in various cell functions, particularly macrophages and dendritic cells for cancer immunity as well as autoimmunity.

Limin Shang
Limin Shang
Pharmacology Director
LightChain Bioscience
Limin Shang
Pharmacology Director
LightChain Bioscience

After obtaining a PhD in pharmacology from SUNY Buffalo, NY, Limin worked on preclinical disease models for several years at Roswell Park Cancer Institute and Mount Sinai School of Medicine, NY. At Novimmune since 2009, he was involved in the preclinical development of several therapeutic antibody programs in autoimmunity and κλ body bispecific antibody programs in immuno-oncology.

In July 2019, Novimmune has been rebranded as “Light Chain Bioscience – A brand of Novimmune SA, and continues to work on novel bispecific technology and associated programs. As the director of pharmacology at Light Chain Bioscience, Limin is in charge of the pharmacological characterization of all bispecific antibody programs.

Dr. Adam Foley-Comer
Dr. Adam Foley-Comer
Chief Medical Officer
KAHR Medical
Dr. Adam Foley-Comer
Chief Medical Officer
KAHR Medical

Drug development professional with over 20 years of clinical and industry experience in Global CRO, big Pharma and Biotechnology companies. Worked at Roche and Quintiles developing expertise in the design and conduct of early phase clinical studies (>100 trials). Oncology experience gained from role as clinical pharmacologist for Avastin franchise and leading clinical development programs in Israeli biotech companies.

André Veillette
André Veillette
Professor, Department of Medicine
University of Montreal
André Veillette
Professor, Department of Medicine
University of Montreal

André Veillette is a world-recognized scientist interested in signal transduction mechanisms in the immune system. Over the past two and a half decades, he has identified and characterized numerous intracellular molecules and receptors that play a crucial role in normal immune regulation.

Anthony Schwartz
Anthony Schwartz
Chief Executive Officer
Morphiex Biotherapeutics
Anthony Schwartz
Chief Executive Officer
Morphiex Biotherapeutics

Anthony Schwartz, Ph.D. is the Chief Executive Officer of Morphiex Biotherapeutics where he is leading efforts to move its SIRPa and thrombospondin-1 inhibitor through early-stage clinical trials. Before Morphiex, Anthony worked with the NIH/NCI to develop novel CD47 therapies for cancer. He’s founded over 10 companies, obtained FDA approval and pushed several drugs through IND studies. Anthony is also a professor at Johns Hopkins University.

Sebastian Nijman
Sebastian Nijman
Founder and Managing Director
Scenic Biotech
Sebastian Nijman
Founder and Managing Director
Scenic Biotech

Sebastian is a Co-founder and Managing Director of Scenic Biotech, and also holds an Adjunct Group leader and Associate Professor position at the Ludwig Institute for Cancer Research at Oxford University. 

 

Sebastian obtained his PhD from The Netherlands Cancer Institute and was a postdoctoral fellow at the Broad Institute of Harvard and the M.I.T. He was group leader at the Research Center for Molecular Medicine in Vienna from 2007-2014 and is a member of the Young Academy of the Austrian Academy of Sciences. In 2010 he co-founded Haplogen GmbH and was its COO until 2014. At Haplogen, he initiated a partnership with Horizon Discovery, and co-led the subsequent $12Mio acquisition of Haplogen Genomics.

Stephanie Dougan
Stephanie Dougan
Assistant Professor
Dana-Farber Cancer Institute
Stephanie Dougan
Assistant Professor
Dana-Farber Cancer Institute

Stephanie Dougan received her PhD in Immunology from Harvard University. She then performed a postdoctoral fellowship with Hidde Ploegh at Whitehead Institute. Dr. Dougan joined the faculty at Harvard Medical School and Dana-Farber Cancer Institute in 2014, where her lab uses unique preclinical models to study the immune response to pancreatic cancer. She is particularly interested in why pancreatic cancer has been so refractory to immunotherapy, and has been developing new immunotherapies for this devastating disease. Dr. Dougan’s lab uses alpaca-derived antibodies to deliver cytokine-based immunotherapies to tumors, and uses an alpaca antibody against mouse CD47 to study the role of CD47 in syngeneic tumor models. Dr. Dougan is a Pew-Stewart Scholar in Cancer Research, a Bill and Melinda Gates Global Health Innovation Scholar, a Melanoma Research Alliance Young Investigator, and received a Pathway to Leadership Award from the Pancreatic Cancer Action Network and AACR. She is also dedicated to training young scientists, and received a Young Mentor Award from Harvard Medical School in 2019.

Dan Pereira
Dan Pereira
CSO
Arch Oncology
Dan Pereira
CSO
Arch Oncology

Dan Pereira, PhD, is Chief Scientific Officer at Arch Oncology, a privately held, clinical stage  biotechnology company  developing AO-176, a highly differentiated CD47 antibody, and advancing an immuno-oncology focused pipeline.

Prior to joining Arch Oncology, he served as Vice President, Discovery Research at Agensys/Astellas and before Agensys was Site Head and Vice President, Research at Arius/Hoffmann-La Roche Limited. Dr. Pereira began his industry career at ImClone Systems where he was Director, Tumor Biology.

Sergio Trombetta
Sergio Trombetta
Senior Principal Scientist, Cancer Immunology & Immune Modulation
Boehringer Ingelheim
Sergio Trombetta
Senior Principal Scientist, Cancer Immunology & Immune Modulation
Boehringer Ingelheim

Sergio Trombetta obtained his PharmD, PhD from the University of Buenos Aires and did postdoctoral research at Yale Medical School. He joined the Cancer immunology and Immune Modulation Program at Boehringer Ingelheim in 2017, where he has been developing novel immune therapies for oncology and inflammatory conditions.

Michael Dougan
Michael Dougan
Assistant Professor, Medicine
Harvard Medical School
Michael Dougan
Assistant Professor, Medicine
Harvard Medical School

Dr. Dougan is currently an Assistant Professor of Medicine at Massachusetts General Hospital and Harvard Medical School and is the Director of the Immunotherapy Mucosal Toxicities Program at Massachusetts General Hospital. He received his MD and PhD from Harvard Medical School. Dr. Dougan’s research focuses on the balance between antitumor responses and immune toxicities.

Timothy Zheng
Timothy Zheng
Executive Director, Immune Modulation
Boehringer Ingelheim
Timothy Zheng
Executive Director, Immune Modulation
Boehringer Ingelheim

Tim Zheng currently is the Executive Director of Immune Modulation at Boehringer Ingelheim. Tim received his PhD degree in Immunology at Yale in 1999, studying the roles of mammalian caspases using gene targeting. Following his training, Tim joined Biogen’s Immunology Research Department and during his 17 year’s tenure at Biogen, he studied extensively the role of cytokine signaling pathways in tissue inflammation and remodeling processes in both physiological and pathological settings, in particular those of the TNF superfamily members. Tim’s work at Biogen led to several IND filings of both biologics (anti-TWEAK & anti-OSMR mAbs) and small molecule drug candidates (Syk and Btk Inhibitors), as well as the successful BLA filing of Daclizumab (anti-CD25) in multiple sclerosis. Tim authored over 60 publications in peer reviewed journals and served on the study sections of both Arthritis Foundation and Scleroderma Research Foundation. Tim joined BI in 2016 to build and lead the Immune Modulation group in the US (Ridgefield, CT) to explore and exploit the full therapeutic potentials of immunomodulatory mechanisms in human diseases.

Zhengyi Wang
Zhengyi Wang
Senior Director of R&D
I-Mab Biopharma
Zhengyi Wang
Senior Director of R&D
I-Mab Biopharma

Dr. Zhengyi Wang is the co-founder and Executive Director of R&D in I-Mab Biopharma. He has taken on a leadership role in the antibody discovery and translational research in the company. Prior to joining I-Mab, Dr Wang worked for GSK R&D China in the early drug discovery targeting the neuro-inflammatory diseases. Dr Wang holds a Ph.D in immunology from the Chinese Academy of Sciences.

Agenda

  • Conference Day 1: Wednesday, March 18th, 2020
  • Conference Day 2: Thursday, March 19th, 2020
Conference Day 1: Wednesday, March 18th, 2020
8.00
Registration, Breakfast & Networking
9.00
Chair’s Opening Remarks & Setting the Scene
  • A look at the day ahead – what will be the key takeaways we should achieve by the end of this summit?
  • How far have we come in the CD47|SIRPα space since last April?

Kipp Weiskopf, Whitehead Fellow, Whitehead Institute

9:10
Keynote Presentation: Fundamental Biology of the CD47|SIRPα Checkpoint

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

9:35
Panel Discussion and Open Q&A: What Impact is our Current Level of Understanding of the CD47|SIRPα Checkpoint Having on the Industry?
  • What knowledge do we need to further the development of CD47|SIRP​α​ targeted therapies
  • What are the specific hurdles within research that prevents information about the CD47|SIRP​α​ being discovered?
  • Do we understand sufficiently which immune functions are controlled by CD47-SIRPα and how?
  • What is the fundamental role of SIRP​α ​on tumors?
  • As we move further into human trials, what are we expecting to learn about the fundamental biology of CD47/SIRPa?

Dan Pereira, CSO, Arch Oncology

Michal Caspi Tal, Instructor & Team Lead, Stanford University

Anthony Schwartz, CEO, Morphiex

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, Sanquin Research, Amsterdam University Medical Center

10:20
Morning Refreshments and Networking
11:20
Presentation: What Do We Know About the Fundamental Biology Behind Alternative SIRP Homologs and an Overview of OSE Immunotherapeutics’ Approach

Nicolas Poirier, Chief Scientifc Officer, OSE Immunotherapeutics

11:45
Presentation: How Do Macrophages Work In Relation To CD47|SIRPα?
  • We learn more about the fundamental biology behind macrophages and how they interact with CD47.  
  • Why macrophages rather than dendritic/myeloid cells? 
  • What is the role of macrophage polarity as it pertains to promoting phagocytosis following SIRPa/CD47 blockade?

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute

12:10
Panel Discussion and Open Q&A: What Does “Eat Me” Mechanistically Mean for Macrophages In Relation To CD47|SIRPα?
  • How do we activate and how do we increase macrophage activity? 
  • What are the different types of macrophages, does the targeted therapy approach need to change depending on the type of macrophage?
  • Can CD47/SIRPa blockade single handedly influence what macrophages do with the tumor antigens after they are ‘eaten’?
  • What other signals/pathways in macrophages need to be engaged?
  • How do we measure/confirm macrophage phagocytosis in a clinical trial setting? 

Siddhartha Mitra, Assistant Professor, University of Colorado

Sergio Trombetta, Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim

Stephanie Dougan, Assistant Professor, Dana-Farber Cancer Institute

Takashi Matozaki, Professor, Dean of the Graduate School of Medicine, Kobe University

12:50
Lunch and Networking

Combinations in Action

2:00
Presentation: QPCTL - A Druggable Modifier of the CD47/SIRP Therapeutic Axis

Sebastian Nijman, Founder & Managing Director, Scenic Biotech

2:25
Panel Discussion and Open Q&A: Chemotherapy, T-cell Immunotherapy and Radiotherapy - Where do these Fit in Combination with CD47|SIRPα?
  • What do we know so far about combining these targets with CD47|SIRPα both preclinically and clinically?
  • How effectively does radiotherapy work alongside CD47|SIRPα
  • What are the risks of combining these immuno-oncology targets?
  • What are the potential impacts of immunogenic vs non-immunogenic cell killing on CD47|SIRPα compounds, does one route work better than the other? 
  • How predictive/how useful are preclinical models in this space?

Siddhartha Mitra, Assistant Professor, University of Colorado

André Veillette, Professor, Department of Medicine, University of Montreal

Timothy Zheng, Executive Director, Immune Modulation, Boehringer Ingelheim

3:05
Afternoon Refreshments and Networking

CD47|SIRPα in the Clinic

4:10
Presentation: Tackling Solid Cancers using a Bispecific Antibody Approach - Light Chain Bioscience
  • A look at the advantages of targeting CD47 with a bispecific antibody approach. 
  • We hear about Mesothelin as a target for solid cancers. 
  • An insight into preclinical data for the CD47 x Mesothelin bispecific antibody.

Limin Shang, Pharmacology Director, LightChain Bioscience

4:35
Presentation: An Insight into I-Mab Biopharma’s progress with TJC4.

Zhengyi Wang, Senior Director of R&D, I-Mab Biopharma

5:00
Panel Discussion and Open Q&A: What are the Predictive Biomarkers Arising when Targeting CD47|SIRPα Pathways?
  • What are the best biomarker strategies to validate how clinical trials are going?
  • SIRPα/CD47 tumoral expression: is there any correlation with clinical efficacy?
  • Macrophage/T-cell infiltrates: is there any correlation with clinical efficacy?
  • What other biomarkers should be considered in regards to CD47|SIRPα drugs? 
  • What biomarkers are biotech companies using to track macrophages in clinic?

Weimin Tang, Global Business Head & Executive VP,  I-Mab Biopharma

André Veillette, Professor, Department of Medicine,University of Montreal

Ferenc Scheeren, Senior Scientist, Leiden University Medical Center

5:40
Close of Day 1
Download Agenda
Conference Day 2: Thursday, March 19th, 2020
9:00
Chair’s Opening Remarks & Setting the Scene
  • What have we learnt so far at CD47|SIRPα 2020? 
  • What can we expect from today?

Siddhartha Mitra, Assistant Professor, University of Colorado

9:10
Presentation: An Insight Into Innovent Biologics’ progress with their CD47|Sirpα targeted therapies.

Junjian Liu, VP, Biologics Discovery, Innovent Biologics

9:35
Presentation: Genetic Variations in SIRPa Impact CD47 Interactions.

Michal Caspi Tal, Instructor & Team Lead, Stanford University

Building Clinical Best Practice

10:00
Panel Discussion and Open Q&A: How Can we Manage Toxicity and Improve Clinical Practice?
  • What toxicities have been identified during preclinical & clinical trials? 
  • Are there specific causes for toxicity and how can we negate these? 
  • Are pre-clinical non-human samples posing problems for future clinical trials? 
  • The RACE For Children Act comes into effect in August 2020, how will this affect clinical trials?
  • How else can we build best practices in clinic? 

Katherine Warren, Clinical Director, Pediatric Neuro-Oncology, Dana Farber Cancer Institute 

Michael Dougan, Assistant Professor, Medicine, Harvard Medical School

Sophia Randolph, CMO, ALX Oncology 

10:40
Morning Refreshments and Networking

Additional Pathways – What Else Is In The Pipeline?

11:30
Presentation: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity

Taylor Schreiber, CSO, Shattuck Labs

11:55
Presentation: We hear more from Arch Oncology and their anti CD47 targeted therapies.

Dan Pereira, CSO, Arch Oncology

12:20
Presentation: An Insight into KAHR Medical’s Progress with DSP107 in combination with PD-L1.

Dr. Adam Foley-Comer, CMO, KAHR Medical

12:45
Lunch

What’s On The Horizon?

2:15
Panel Discussion and Open Q&A: Reflection and Progression - Where are We and What’s Next for CD47|SIRPα?
  • What challenges have we faced and how can we overcome these?
  • Where do we expect to see the most growth in the next year? 
  • Should enhancing mediated-macrophage phagocytosis be a focus going forward? 
  • How is the future work on emerging “don’t eat me signals” going to benefit from our work with CD47/SIRPα?
  • What have been our biggest takeaways from the CD47/SIRPa 2020 Summit

Dr. Adam Foley-Comer, CMO, KAHR Medical 

Timothy Zheng, Executive Director, Immune Modulation, Boehringer Ingelheim

Taylor Schreiber, CSO, Shattuck Labs

2:55
Chair's Closing Remarks
  • What have been the key learnings from CD47|SIRPα 2020?

Siddhartha Mitra, Assistant Professor, University of Colorado

3:00
Close of CD47|SIRPa 2020
Download Agenda

Partnership

Our attendees tell us that one of the main reasons they attend our summits is to advance partnership discussions and forge new business relationships.  To facilitate this (and help us fund the event) we have a limited number of partnership opportunities available. This means that our partners can be confident that they can have meaningful conversations – and our attendees know that the composition of the audience is just right.

We invite you to get in touch for a no-obligation conversation.  We will share our audience data with you and help you determine whether this summit is the right fit to facilitate your goals.

Contact Us +
Partnership

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration